Tuberkuloz ve toraks · 2015
[Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karaboğa Burcu, Çilli Aykut
Аннотация
INTRODUCTION: For hospitalized patients, monotherapy with a respiratory Fluoroquinolone (F) and dual therapy combination a ampicilline-sulbactam + a macrolide (AS+M) are extensively used in the treatment of community-acquiredpneumonia (CAP). In this study, empirical AS + M combination therapy versus F monotherapy was compared in hospitalized adult CAP patients.
PATIENTS AND METHODS: This retrospective study, patients with CAP hospitalized in Akdeniz University Hospital, Pulmonology Clinic between October 2009 and May 2013 were included in the study.
RESULTS: During the study period, 123 patients received AS + M and 75 received F. Mean age was 66 years. The most frequent comorbidities were diabetes mellitus, chronic obstructive pulmonary disease and cardiovascular disease. Disease severity, age, sex, comorbid diseases, smoking history, laboratory findings, CURB-65 and PSI scores were similar for the two treatment groups at admission. The clinical success rate cure was similar for both groups (82.1% vs 88%; p= 0.314). Length of hospital stay (5.6 ± 3.9 days vs 5.9 ± 3.9 days, p= 0.223) and hospital cost (1.963 ± 3.723 TL vs 1.965 ± 7.172 TL, p= 0.975) were also nonsignificant in both groups. In-hospital, 30-day and 90-day mortality rates were not different in AS + M and F group (5.6% vs 6.6; 8.1% vs 8%; 20.3% vs 19%; 31.7% vs 26.9%, respectively).
CONCLUSIONS: In conclusion, our study has showed ampicilline-sulbactam and macrolide combination and fluoroquinolone monotherapy have comparable clinical efficacy as well as mortality rates in hospitalized patients with CAP.
PATIENTS AND METHODS: This retrospective study, patients with CAP hospitalized in Akdeniz University Hospital, Pulmonology Clinic between October 2009 and May 2013 were included in the study.
RESULTS: During the study period, 123 patients received AS + M and 75 received F. Mean age was 66 years. The most frequent comorbidities were diabetes mellitus, chronic obstructive pulmonary disease and cardiovascular disease. Disease severity, age, sex, comorbid diseases, smoking history, laboratory findings, CURB-65 and PSI scores were similar for the two treatment groups at admission. The clinical success rate cure was similar for both groups (82.1% vs 88%; p= 0.314). Length of hospital stay (5.6 ± 3.9 days vs 5.9 ± 3.9 days, p= 0.223) and hospital cost (1.963 ± 3.723 TL vs 1.965 ± 7.172 TL, p= 0.975) were also nonsignificant in both groups. In-hospital, 30-day and 90-day mortality rates were not different in AS + M and F group (5.6% vs 6.6; 8.1% vs 8%; 20.3% vs 19%; 31.7% vs 26.9%, respectively).
CONCLUSIONS: In conclusion, our study has showed ampicilline-sulbactam and macrolide combination and fluoroquinolone monotherapy have comparable clinical efficacy as well as mortality rates in hospitalized patients with CAP.